BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading JNJ charts…

Search ticker or company⌘K

JNJ

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

JNJ · Johnson & Johnson fundamentals · vpside

vpside

⌘K

JNJMarket cap $669B/Last filing 10-Q, Q3 FY26 · 21 Oct 2026/JNJMarket cap $669B/Last filing 10-Q, Q3 FY26 · 21 Oct 2026/JNJMarket cap $669B/Last filing 10-Q, Q3 FY26 · 21 Oct 2026/JNJMarket cap $669B/Last filing 10-Q, Q3 FY26 · 21 Oct 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

JNJ

Johnson & Johnson

NYSE · Pharmaceutical preparations (SIC 2834) · FY ends 3 Jan

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$25.40B+5.9% year on year

$30B$20B$10B$0

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 21 Oct 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

67.6%−0.5 pp year on year

72%70%68%66%

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 21 Oct 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$16.91B−7.2% year on year

$40B$20B$0

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 21 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$20.59B+5.1% year on year

$30B$20B$10B$0

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 21 Oct 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters